Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2020-10-21 Regulatory Filings
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
Pause in Trading 1 page 111.1KB
Regulatory Filings Classification · 95% confidence The document is a short market release announcing a temporary pause in trading of the company's securities. It does not contain financial data, report content, or detailed information about management, capital, or legal matters. It is a regulatory announcement related to trading status, fitting best under general regulatory announcements.
2020-10-21 English
Trading Halt 2 pages 214.4KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Antisense Therapeutics Limited regarding a trading halt requested pending the release of an announcement about the FDA response to an orphan drug designation request. It is a short notice about a trading halt and does not contain any financial data, report content, or detailed disclosures. It is not a financial report, earnings release, or any detailed filing but rather a regulatory announcement related to trading status. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-10-21 English
Quarterly Update and Appendix 4C 8 pages 291.0KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Update & Appendix 4C' and includes detailed financial data such as cash flow statements for the quarter ended 30 September 2020. It contains substantive financial information including cash flows from operating, investing, and financing activities, as well as operational updates and regulatory interactions. The presence of Appendix 4C, which is a quarterly cash flow report required by the ASX Listing Rules, confirms this is a quarterly financial report. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2021
2020-10-20 English
ATL1102 shows significant improvement vs external control 14 pages 1.7MB
Investor Presentation Classification · 95% confidence The document is a detailed announcement of clinical trial results for ATL1102 treatment in non-ambulant boys with Duchenne Muscular Dystrophy (DMD). It includes statistical data, comparisons to a control group, and scientific commentary. The content is focused on presenting new clinical data and its significance, rather than financial results or regulatory filings. It is not a full annual or interim financial report, nor is it a transcript of a call or a governance or management change announcement. The document is a comprehensive presentation of clinical trial outcomes intended for investors and the public, which aligns with the characteristics of an Investor Presentation (IP). The length (15,000 characters) and detailed data support this classification rather than a brief announcement or regulatory filing.
2020-10-01 English
US FDA Grants RPDD to ATL1102 for the treatment of DMD 2 pages 152.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 30 September 2020 regarding the US FDA granting Rare Pediatric Disease Designation to ATL1102 for the treatment of Duchenne Muscular Dystrophy (DMD). It discusses regulatory designations, potential benefits of a priority review voucher, and company background. The content is an announcement of a regulatory milestone and strategic update rather than a financial report, earnings release, or detailed management discussion. It does not contain financial statements or detailed financial data. The document is relatively short (6891 characters) and serves as a news release about regulatory progress and potential capital benefits from the FDA designation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and compliance-related disclosures that do not fit other specific categories.
2020-09-29 English
Antisense to present new data at WMS Virtual Congress 2020 2 pages 150.0KB
Investor Presentation Classification · 95% confidence The document is an announcement about new clinical data (ATL1102 in DMD) to be presented at a scientific congress (World Muscle Society Virtual Congress 2020). It mentions a poster presentation and an investor webinar, but does not contain any financial statements, detailed financial analysis, or regulatory filings. The content focuses on scientific and clinical data presentation and investor communication rather than a formal financial report or regulatory filing. The document length is 6333 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication of financial results, audit information, management discussion, or other report types. Therefore, this document is best classified as an Investor Presentation (IP) because it is a detailed presentation for investors focusing on clinical data and company updates relevant to investment decisions.
2020-09-28 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.